NATCO Pharma Limited (NSE:NATCOPHARM)
India · Delayed Price · Currency is INR 865.00
-3.30 (-0.38%)
Jun 9, 2026, 3:30 PM IST
NATCO Pharma Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, NATCO Pharma stock has a consensus rating of "Hold" and an average price target of ₹1,021. The average 1-year stock price forecast is 18.06% higher than the current stock price, while the lowest is ₹712.00 (-17.69%) and the highest is ₹1,220 (+41.04%).
Price Target: ₹1,021 (+18.06%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for NATCO Pharma stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Hold | 3 | 4 | 3 | 3 | 3 | 3 |
| Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 3 | 3 | 3 | 3 | 2 | 2 |
| Total | 11 | 11 | 11 | 11 | 10 | 10 |
Financial Forecast
Revenue This Year
33.26B
from 40.78B
Decreased by -18.45%
Revenue Next Year
36.74B
from 33.26B
Increased by 10.46%
EPS This Year
40.30
from 79.20
Decreased by -49.12%
EPS Next Year
45.80
from 40.30
Increased by 13.65%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 35.0B | ||
| Avg | 33.3B | ||
| Low | 28.4B |
Revenue Growth
| Revenue Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | -14.3% | ||
| Avg | -18.4% | ||
| Low | -30.4% |
EPS Forecast
| EPS | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 44.00 | ||
| Avg | 40.30 | ||
| Low | 31.30 |
EPS Growth
| EPS Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | -44.4% | ||
| Avg | -49.1% | ||
| Low | -60.5% |